BIRC5 and Miyoshi myopathy: Carfilzomib is known to induce a mitochondrial deficit in resistant MM cells in vitro in a mitochondria-derived activator of caspase (SMAC)-Survivin dependent manner leading to increased apoptosis, mitochondrial-derived ROS release and inhibition of mitochondrial respiration, which is in line with our data [48,49].